Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma

Laurence Zitvogel; Guido Guido Kroemer

doi:10.1158/2643-3230.bcd-21-0059

Abstract

1 min read

Abstract Summary: As a general rule, successful antineoplastic treatments induce an antitumor immune response, even if they were initially designed to target cancer cell–autonomous pathways. In this issue of Blood Cancer Discovery, Gulla and colleagues reveal that the proteasome inhibitor bortezomib induces immunogenic stress and death in multiple myeloma cells, thus explaining its therapeutic efficacy. See related article by Gulla et al., p. 468.

Related publications

Article2024

Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma

Liwei Zhao, Zhe Shen, Guido Guido Kroemer, Oliver Kepp

Article2018

The anticancer peptide RT53 induces immunogenic cell death

Ewa Pasquereau-Kotula, Justine Habault, Guido Guido Kroemer, Jean‐Luc Poyet

Article2007

Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition

Silke Meister, Ulrich Sigmar Schubert, Kirsten Neubert, Kai Herrmann, Renate Burger, Martin Gramatzki, Sabine Hahn, Sandra Schreiber, Sabine Wilhelm, Martin Herrmann, Hans‐Martin Jäck, Reinhard Voll

Article2019

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Peng Liu, Liwei Zhao, Jonathan Pol, Sarah Lévesque, Adriana Petrazzuolo, Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Takahiro Yamazaki, Kristina Iribarren, Laura Senovilla, Lucillia Bezu, Erika Vacchelli, Valentina Sica, Andréa Melis, Tiffany Martin, Lin Xia, Heng Yang, Qingqing Li, Jinfeng Chen, Sylvère Durand, Fanny Aprahamian, Déborah Lefevre, Sophie Broutin, Angélo Paci, ,

Article2025

Patritumab deruxtecan induces immunogenic cell death

Sabrina Forveille, Liwei Zhao, Allan Sauvat, Giulia Cerrato, Marion Leduc, Flora Doffe, Yuhong Pan, Peng Liu, Guido Guido Kroemer, Oliver Kepp